P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. (Q50891100)

24 March 2018

title

P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. (English)

1 reference

24 March 2018

main subject

temporal lobe epilepsy

1 reference

11

1 reference

24 March 2018

Martin Bauer

12

1 reference

24 March 2018

Oliver Langer

13

1 reference

24 March 2018

Christian Vollmar

16

1 reference

24 March 2018

John S. Duncan

17

1 reference

24 March 2018

Adam McMahon

Adam McMahon

5

0 references

Joan Liu

Joan Liu

3

0 references

Rainer Hinz

Rainer Hinz

10

0 references

Matthew C. Walker

Matthew Walker

7

1 reference

ORCID Public Data File 2021

author name string

Maria Feldmann

1

1 reference

24 March 2018

Marie-Claude Asselin

2

1 reference

24 March 2018

Shaonan Wang

4

1 reference

24 March 2018

José Anton-Rodriguez

6

1 reference

24 March 2018

Mark Symms

8

1 reference

24 March 2018

Gavin Brown

9

1 reference

24 March 2018

Maria Thom

14

1 reference

24 March 2018

Terry Jones

15

1 reference

24 March 2018

Sanjay M Sisodiya

18

1 reference

24 March 2018

Matthias J Koepp

19

1 reference

24 March 2018

publication date

18 June 2013

1 reference

24 March 2018

published in

Lancet Neurology

1 reference

24 March 2018

volume

12

1 reference

24 March 2018

issue

8

1 reference

24 March 2018

page(s)

777-785

1 reference

24 March 2018

Early identification of refractory epilepsy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

MDR1 gene expression in brain of patients with medically intractable epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Expression and cellular distribution of high- and low-affinity neurotrophin receptors in malformations of cortical development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Membrane transporters in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

A study on statistically reliable and computationally efficient algorithms for generating local cerebral blood flow parametric images with positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Testing for anatomically specified regional effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

A "silent" polymorphism in the MDR1 gene changes substrate specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Revising the "Rule of Three" for inferring seizure freedom

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970109-1

7 January 2021

10.1016/S1474-4422(13)70109-1

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018